AR038203A1 - Cuerpos de inclusion de fosfolipidos y uso de los mismos en tratamientos medicos - Google Patents
Cuerpos de inclusion de fosfolipidos y uso de los mismos en tratamientos medicosInfo
- Publication number
- AR038203A1 AR038203A1 ARP030100173A ARP030100173A AR038203A1 AR 038203 A1 AR038203 A1 AR 038203A1 AR P030100173 A ARP030100173 A AR P030100173A AR P030100173 A ARP030100173 A AR P030100173A AR 038203 A1 AR038203 A1 AR 038203A1
- Authority
- AR
- Argentina
- Prior art keywords
- synthetic
- inclusion bodies
- groups
- bodies
- inclusion
- Prior art date
Links
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01G—COMPOUNDS CONTAINING METALS NOT COVERED BY SUBCLASSES C01D OR C01F
- C01G19/00—Compounds of tin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82B—NANOSTRUCTURES FORMED BY MANIPULATION OF INDIVIDUAL ATOMS, MOLECULES, OR LIMITED COLLECTIONS OF ATOMS OR MOLECULES AS DISCRETE UNITS; MANUFACTURE OR TREATMENT THEREOF
- B82B3/00—Manufacture or treatment of nanostructures by manipulation of individual atoms or molecules, or limited collections of atoms or molecules as discrete units
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01G—COMPOUNDS CONTAINING METALS NOT COVERED BY SUBCLASSES C01D OR C01F
- C01G15/00—Compounds of gallium, indium or thallium
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09D—COATING COMPOSITIONS, e.g. PAINTS, VARNISHES OR LACQUERS; FILLING PASTES; CHEMICAL PAINT OR INK REMOVERS; INKS; CORRECTING FLUIDS; WOODSTAINS; PASTES OR SOLIDS FOR COLOURING OR PRINTING; USE OF MATERIALS THEREFOR
- C09D5/00—Coating compositions, e.g. paints, varnishes or lacquers, characterised by their physical nature or the effects produced; Filling pastes
- C09D5/24—Electrically-conducting paints
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Nanotechnology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Dispersion Chemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Crystallography & Structural Chemistry (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Endocrinology (AREA)
- Psychology (AREA)
- Medical Informatics (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
Abstract
Composiciones sintéticas y semi-sintéticas que presentan actividad biológica y uso de las mismas en el tratamiento y/o la profilaxis de diversos trastornos en pacientes mamíferos. Preparación y el uso de cuerpos de inclusión sintéticos y semi-sintéticos que, después de su introducción en el cuerpo de un paciente, producen efectos benéficos anti-inflamatorios, protectores de órganos e inmunoreguladores. Tratamientos y composiciones para aliviar enfermedades inflamatorias y autoinmunes y los síntomas de las mismas. Reivindicación 1: Una composición de materia que comprende cuerpos de inclusión, que presentan una pluralidad de grupos químicos reactivos que tienen la capacidad para interactuar con los receptores presentes sobre las células del sistema inmune de mamíferos para alterar el perfil de citoquinas del sistema inmune a favor de una anti-inflamación, donde dichos cuerpos de inclusión presentan un tamano de aproximadamente 20-1000 nm, con la condición que cuando dichos grupos son todos del mismo tipo, dichos grupos no son serina-fosfato o glicerol-fosfato.
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002368656A CA2368656A1 (en) | 2002-01-21 | 2002-01-21 | Receptor-ligand pairing for anti-inflammatory response |
US5138102A | 2002-01-22 | 2002-01-22 | |
US35142702P | 2002-01-28 | 2002-01-28 | |
US36462002P | 2002-03-18 | 2002-03-18 | |
US37210602P | 2002-04-15 | 2002-04-15 | |
US40085702P | 2002-08-02 | 2002-08-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR038203A1 true AR038203A1 (es) | 2005-01-05 |
Family
ID=27617925
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP030100173A AR038203A1 (es) | 2002-01-21 | 2003-01-21 | Cuerpos de inclusion de fosfolipidos y uso de los mismos en tratamientos medicos |
ARP030100172A AR047005A1 (es) | 2002-01-21 | 2003-01-21 | Cuerpos de inclusion que transportan glicerol-fosfato aceptables para uso farmaceutico |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP030100172A AR047005A1 (es) | 2002-01-21 | 2003-01-21 | Cuerpos de inclusion que transportan glicerol-fosfato aceptables para uso farmaceutico |
Country Status (14)
Country | Link |
---|---|
US (3) | US20030175334A1 (es) |
EP (2) | EP1467741A1 (es) |
JP (2) | JP2005515243A (es) |
KR (1) | KR20040089118A (es) |
CN (1) | CN1620301A (es) |
AR (2) | AR038203A1 (es) |
BR (2) | BR0307041A (es) |
CA (5) | CA2368656A1 (es) |
EA (1) | EA007426B1 (es) |
MA (1) | MA27168A1 (es) |
MX (1) | MXPA04007042A (es) |
PE (1) | PE20030973A1 (es) |
TW (2) | TWI283181B (es) |
WO (3) | WO2003061666A1 (es) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050058698A1 (en) * | 2002-01-21 | 2005-03-17 | Nolan Yvonne Mairead | Pharmaceutically acceptable phosphate-glycerol carrying bodies and uses relating to Parkinson's Disease |
WO2004082688A1 (en) * | 2003-03-20 | 2004-09-30 | Vasogen Ireland Limited | Phosphatidylglycerol (pg) receptor agonists and antagonists |
KR20060037369A (ko) * | 2003-07-21 | 2006-05-03 | 바소겐 아일랜드 리미티드 | 급성 염증 상태의 치료를 위한 포스페이트 글리세롤 기를함유하는 리포솜 |
US20060008517A1 (en) * | 2004-07-09 | 2006-01-12 | Lynch Marina A | Treatment of age-related memory impairment |
PE20060661A1 (es) * | 2004-09-15 | 2006-09-16 | Vasogen Ireland Ltd | Composicion que comprende liposomas para el tratamiento de escleorosis multiple |
WO2006107107A1 (ja) * | 2005-04-01 | 2006-10-12 | Fumitaka Ohsuzu | リン脂質小胞体を含む心筋保護剤および虚血・再潅流時の心筋障害を予防する方法 |
CA2622475A1 (en) * | 2005-09-26 | 2007-04-05 | Vasogen Ireland Limited | Treatment of inflammation and vascular abnormalities of the eye |
EP1933813A4 (en) * | 2005-10-11 | 2013-02-27 | Univ Pittsburgh | SPHINGOMYELIN LIPOSOME FOR THE TREATMENT OF HYPERACTIVE BLADDER DISORDER |
WO2007131329A1 (en) * | 2006-05-12 | 2007-11-22 | Vasogen Ireland Limited | Treatment of ubiquitin-proteasome system dysfunction related disorders |
JP2013502436A (ja) | 2009-08-21 | 2013-01-24 | ターゲッティド デリバリー テクノロジーズ リミテッド | 小胞状の製剤 |
GB201205642D0 (en) | 2012-03-29 | 2012-05-16 | Sequessome Technology Holdings Ltd | Vesicular formulations |
LT2861214T (lt) * | 2012-06-14 | 2020-12-28 | Universität Bern | Specialiai pritaikytos liposomos, skirtos bakterinių infekcijų gydymui |
JP6417648B2 (ja) * | 2013-07-30 | 2018-11-07 | 株式会社豊田中央研究所 | エタノールアミンリン酸の利用 |
CA2946275A1 (en) * | 2014-04-04 | 2015-10-08 | Osaka University | Drug delivery enhancer comprising substance for activating lysophospholipid receptors |
JP6103143B1 (ja) * | 2015-05-18 | 2017-03-29 | 不二製油株式会社 | IL−1β産生抑制作用を有する食品添加用組成物 |
WO2017001625A1 (en) | 2015-06-30 | 2017-01-05 | Sequessome Technology Holdings Limited | Multiphasic compositions |
EP3589278A1 (en) * | 2017-03-02 | 2020-01-08 | Combioxin SA | Liposomes for inhibiting biofilm formation |
CN115531399A (zh) * | 2022-09-15 | 2022-12-30 | 首都医科大学 | 溶血磷脂酰胆碱在治疗阿尔茨海默病中的应用 |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2518718A1 (fr) * | 1981-12-23 | 1983-06-24 | Djelalian Madeleine | Procede pour capter et exploiter au maximum le rayonnement solaire global, dispositifs pour la mise en oeuvre de ce procede et capteurs solaires en resultant |
US4485054A (en) * | 1982-10-04 | 1984-11-27 | Lipoderm Pharmaceuticals Limited | Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV) |
US4789633A (en) * | 1984-04-19 | 1988-12-06 | University Of Tennessee Research Corporation | Fused liposome and acid induced method for liposome fusion |
US4946787A (en) * | 1985-01-07 | 1990-08-07 | Syntex (U.S.A.) Inc. | N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
US5192528A (en) * | 1985-05-22 | 1993-03-09 | Liposome Technology, Inc. | Corticosteroid inhalation treatment method |
US4812314A (en) * | 1986-02-24 | 1989-03-14 | Yissum Research & Dev. Co. Of The Hebrew Univ. Of Jerusalem And Hadassah Medical Organization | Lipid replacement therapy |
US5252263A (en) * | 1986-06-16 | 1993-10-12 | The Liposome Company, Inc. | Induction of asymmetry in vesicles |
US5229376A (en) * | 1986-09-25 | 1993-07-20 | The United States Of America As Represented By The Secretary Of The Army | Encapsulated plant-derived phosphatidylinositol (PI) compositions for the prevention of mitogenically induced cell proliferation |
US4963297A (en) * | 1987-12-22 | 1990-10-16 | The Liposome Company, Inc. | Spontaneous vesticulation of multilamellar liposomes |
US4863739A (en) * | 1987-05-19 | 1989-09-05 | Board Of Regents, The University Of Texas System | Liposome compositions of anthracycline derivatives |
FR2617170B1 (fr) * | 1987-06-25 | 1989-12-22 | Inst Nat Sante Rech Med | Nouveaux derives peptidiques et leur application notamment en therapeutique |
IL93996A0 (en) * | 1989-04-04 | 1991-01-31 | Alcon Lab Inc | Pharmaceutical composition containing a liposome |
JP3010500B2 (ja) * | 1989-04-18 | 2000-02-21 | ネクスター・フアーマシユーテイカルズ・インコーポレイテツド | 虚血性組織のリポゾームターゲッティング |
FR2658418B1 (fr) * | 1990-02-20 | 1994-09-02 | Synthelabo | Compositions pharmaceutiques a base de phospholipides. |
US5188951A (en) * | 1990-04-17 | 1993-02-23 | The Liposome Company, Inc. | Enzymatic synthesis of soluble phosphatides from phospholipids |
DE4018767A1 (de) * | 1990-06-12 | 1991-12-19 | Braun Melsungen Ag | Wirkstofffreie liposomen zur behandlung von atherosklerose |
US5556637A (en) * | 1990-08-06 | 1996-09-17 | A. Nattermann & Cie. Gmbh | Water containing liposome system |
IT1249063B (it) * | 1991-05-28 | 1995-02-11 | Fidia Spa | Impiego di derivati fosfolipidici per la preparazione di composizioni farmaceutiche aventi attivita' immunosoppressiva |
EP0673384A4 (en) * | 1992-12-10 | 1996-10-09 | Univ Minnesota | POLYPEPTIDES USEFUL IN TREATING INFLAMMABLE DISEASES. |
US5637315A (en) * | 1993-01-04 | 1997-06-10 | Thomas Jefferson University | Treatment of disease states induced by oxidative stress |
ES2072223B1 (es) * | 1993-11-25 | 1996-03-16 | Lipotec Sa | Liposomas encapsulando doxorubicina. |
US5746223A (en) * | 1996-10-11 | 1998-05-05 | Williams; Kevin Jon | Method of forcing the reverse transport of cholesterol from a body part to the liver while avoiding harmful disruptions of hepatic cholesterol homeostasis |
US6139871A (en) * | 1995-07-26 | 2000-10-31 | The University Of British Columbia | Liposome compositions and methods for the treatment of atherosclerosis |
US6773719B2 (en) * | 1994-03-04 | 2004-08-10 | Esperion Luv Development, Inc. | Liposomal compositions, and methods of using liposomal compositions to treat dislipidemias |
US6312719B1 (en) * | 1994-03-04 | 2001-11-06 | The University Of British Columbia | Liposome compositions and methods for the treatment of atherosclerosis |
AU1751795A (en) * | 1994-03-04 | 1995-09-18 | University Of British Columbia, The | Liposome compositions and methods for the treatment of atherosclerosis |
JPH08183740A (ja) * | 1994-12-28 | 1996-07-16 | Nippon Steel Corp | 細胞接着阻害剤及び該阻害剤を含む抗炎症剤 |
US5643599A (en) * | 1995-06-07 | 1997-07-01 | President And Fellows Of Harvard College | Intracellular delivery of macromolecules |
US5741514A (en) * | 1995-08-31 | 1998-04-21 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Method for reducing serum lipoprotein(a) concentration |
CA2229435A1 (en) * | 1995-09-14 | 1997-03-20 | Lxr Biotechnology Inc. | Compositions with anti-apoptotic activity, containing a mixture of phospholipids |
US5736157A (en) * | 1995-10-11 | 1998-04-07 | Williams; Kevin Jon | Method of regulating cholesterol related genes, enzymes and other compounds, and pharmaceutical compositions |
US6491922B1 (en) * | 1996-02-09 | 2002-12-10 | Cornell Research Foundation, Inc. | Methods and compounds for treating autoimmune and vascular disease |
WO1997035560A1 (en) * | 1996-03-28 | 1997-10-02 | The Board Of Trustees Of The University Of Illinois | Materials and methods for making improved echogenic liposome compositions |
US20020115609A1 (en) * | 1997-07-14 | 2002-08-22 | Hayat Onyuksel | Materials and methods for making improved micelle compositions |
JPH11308562A (ja) * | 1998-04-20 | 1999-11-05 | Minolta Co Ltd | デジタルカメラシステム |
US6251932B1 (en) * | 1998-09-25 | 2001-06-26 | Asta Medica Ag | Immunophilin ligands |
WO2002009678A2 (en) * | 2000-07-31 | 2002-02-07 | Ottawa Heart Institute Research Corporation | Charged phospholipid compositions and methods for their use |
-
2002
- 2002-01-21 CA CA002368656A patent/CA2368656A1/en not_active Abandoned
-
2003
- 2003-01-17 CA CA002416791A patent/CA2416791A1/en not_active Abandoned
- 2003-01-21 MX MXPA04007042A patent/MXPA04007042A/es not_active Application Discontinuation
- 2003-01-21 WO PCT/CA2003/000064 patent/WO2003061666A1/en active Application Filing
- 2003-01-21 EA EA200400888A patent/EA007426B1/ru not_active IP Right Cessation
- 2003-01-21 US US10/348,600 patent/US20030175334A1/en not_active Abandoned
- 2003-01-21 AR ARP030100173A patent/AR038203A1/es not_active Application Discontinuation
- 2003-01-21 US US10/348,601 patent/US20040013718A1/en not_active Abandoned
- 2003-01-21 WO PCT/CA2003/000065 patent/WO2003061667A1/en active Application Filing
- 2003-01-21 PE PE2003000064A patent/PE20030973A1/es not_active Application Discontinuation
- 2003-01-21 CN CNA03802537XA patent/CN1620301A/zh active Pending
- 2003-01-21 WO PCT/CA2003/000066 patent/WO2003061620A2/en not_active Application Discontinuation
- 2003-01-21 AR ARP030100172A patent/AR047005A1/es not_active Application Discontinuation
- 2003-01-21 TW TW092101231A patent/TWI283181B/zh not_active IP Right Cessation
- 2003-01-21 JP JP2003561611A patent/JP2005515243A/ja active Pending
- 2003-01-21 TW TW092101236A patent/TW200302281A/zh unknown
- 2003-01-21 CA CA002473490A patent/CA2473490A1/en not_active Abandoned
- 2003-01-21 BR BR0307041-7A patent/BR0307041A/pt not_active IP Right Cessation
- 2003-01-21 KR KR10-2004-7011280A patent/KR20040089118A/ko not_active Application Discontinuation
- 2003-01-21 EP EP20030700266 patent/EP1467741A1/en not_active Withdrawn
- 2003-01-21 JP JP2003561610A patent/JP2005515242A/ja active Pending
- 2003-01-21 CA CA002471740A patent/CA2471740A1/en not_active Abandoned
- 2003-01-21 CA CA002473395A patent/CA2473395A1/en not_active Abandoned
- 2003-01-21 EP EP03700265A patent/EP1467740A1/en not_active Withdrawn
- 2003-01-21 BR BR0307018-2A patent/BR0307018A/pt not_active IP Right Cessation
-
2004
- 2004-07-16 MA MA27788A patent/MA27168A1/fr unknown
-
2007
- 2007-11-28 US US11/946,785 patent/US20080160074A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CN1620301A (zh) | 2005-05-25 |
MA27168A1 (fr) | 2005-01-03 |
JP2005515243A (ja) | 2005-05-26 |
KR20040089118A (ko) | 2004-10-20 |
US20040013718A1 (en) | 2004-01-22 |
EA200400888A1 (ru) | 2005-04-28 |
CA2416791A1 (en) | 2003-07-21 |
MXPA04007042A (es) | 2005-06-20 |
PE20030973A1 (es) | 2003-12-09 |
TW200302281A (en) | 2003-08-01 |
WO2003061620A2 (en) | 2003-07-31 |
WO2003061666A1 (en) | 2003-07-31 |
EA007426B1 (ru) | 2006-10-27 |
AR047005A1 (es) | 2006-01-04 |
WO2003061620A3 (en) | 2003-10-16 |
CA2471740A1 (en) | 2003-07-31 |
WO2003061667A1 (en) | 2003-07-31 |
CA2473490A1 (en) | 2003-07-31 |
EP1467741A1 (en) | 2004-10-20 |
EP1467740A1 (en) | 2004-10-20 |
CA2368656A1 (en) | 2003-07-21 |
US20030175334A1 (en) | 2003-09-18 |
US20080160074A1 (en) | 2008-07-03 |
CA2473395A1 (en) | 2003-07-31 |
JP2005515242A (ja) | 2005-05-26 |
BR0307018A (pt) | 2005-02-09 |
TWI283181B (en) | 2007-07-01 |
BR0307041A (pt) | 2004-10-26 |
TW200302735A (en) | 2003-08-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR038203A1 (es) | Cuerpos de inclusion de fosfolipidos y uso de los mismos en tratamientos medicos | |
ES2106785T3 (es) | Medicamentos, su preparacion y empleo como analgesicos y/o antiinflamatorios para seres humanos y animales. | |
UY29377A1 (es) | Nuevas formilaciones líquidas de rotavirus, su preparación y sus usos. | |
BR9715022A (pt) | Método para tratar de doenças prostáticas usando formulações de vitamina d por liberação sistemática e/ou prolongada | |
BR112014025469B1 (pt) | Usos de lisado filtrado da bactéria probiótica lactobacillus rhamnosus gg atcc 53103 no reparo ou regeneração da barreira cutânea e no tratamento cosmético para aumentar a função de barreira cutânea | |
BR9610929A (pt) | Processos para liberar um ou mais polipeptídeos biologicamente ativos, e um ou mais antígenos, para regular as funções de sobrevivência, crescimento, diferenciação, efetuadora ou suscetibilidade a infeção de células ou tecidos, para refoçar uma resposta imune contra células de tumor ou uma infecção colonizado uma superfície mucosal ou tecido distante ou adjacente, para modular o tipo de resposta imune ( anticorpo versus mediada por célula) contra um agente infeccioso patogênico, para induzir a apoptose em células | |
ATE418324T1 (de) | Mucoadhäsive xyloglucan-haltige formulierung für medizinprodukte und pharmazeutische darreichungsformen | |
DK1071439T3 (da) | Hybenformuleringer som antiinflammatorisk naturmedicin til lindring/reduktion af symptomer associeret med inflammation og artritis | |
BR9307104A (pt) | Preparações reforçadora de mecanismos de defesa de hospedeiros e migrante com pico único b-glicano hidrossolúvel métodos para produzir uma preparação reforçadora de meanismos de defesa de hospedeiros para impedir infecção em um mamífero para estimular o reparo e cura de uma ferida e para estimular a proliferação de plaquetas composição farmacêutica e método para tratar infecção em mamíferos | |
BRPI0112962B8 (pt) | composições farmacêuticas compreendendo ácido hialurônico, ácido glicirretínico e polivinilpirrolidona, e uso desses compostos na preparação de medicamentos | |
ES2657675T3 (es) | Terapia de enfermedad mediante el uso de una preparación farmacéutica tolerogénica | |
BRPI0317064B8 (pt) | composições compreendendo células dendríticas parcialmente amadurecidas in vitro | |
BR0109672A (pt) | Uso de zd6126 ou de um seu sal farmaceuticamente aceitável e um de: um agente antitumoral de plantina e um taxano, composição farmacêutica, produto de combinação, kit, e, método para a produção de um efeito de danificação vascular em um animal de sangue quente | |
ATE50499T1 (de) | Pharmazeutische zusammensetzungen mit gehalt an flavanolignanen und phospholipiden als wirkstoffe. | |
AR052830A1 (es) | Regimen de cladribina para tratar esclerosis multiple | |
ES2571131T3 (es) | Polifenoles de té Oolong que tienen efecto inhibidor sobre la lipasa | |
AR016254A1 (es) | Una composicion de celulas de tumor modificadas con un hapteno o extracto de celulas tumorales y uso de la misma en la elaboracion de un medicamento. | |
HK1055079A1 (en) | Apoptotic entities for use in treatment of t-cell-mediated and inflammatory disorders | |
Paes-Leme et al. | Assessment of Aloe vera (L.) genotoxic potential on Escherichia coli and plasmid DNA | |
AR048806A1 (es) | Uso de cariofilenos en la elaboracion de medicamentos y tratamiento de afecciones corporales de inflamacion y dolor inflamatorio | |
ES2107414T3 (es) | Utilizacion de interferon-beta humano para la estimulacion de la eritropoyesis. | |
Mizgała-Izworska | The role of flavonoids in prevention and treatment of selected skin diseases | |
CO4410174A1 (es) | Preparaciones farmaceuticas de cefixima | |
CN109464328A (zh) | 植物型抑菌止痒液 | |
Shirzad et al. | Effects of royal jelly on sterile skin cut repair |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |